Xeloda Tablet, Film Coated
Product Images NDC 61269-475

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Xeloda (NDC 61269-475). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by H2-pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Xeloda 01)

Chemical structure of capecitabine, the active ingredient in XELODA 500 mg, displayed as a molecular diagram showing its atoms and bonds.*

FDA Label Image

Figure 1 (Xeloda 02)

A survival curve chart comparing two treatment groups: 5-FU plus leucovorin (dashed line) and capecitabine (solid line) over a period of 0 to 96 months since randomization. The y-axis represents survival probability, and the x-axis indicates time in months. Below the x-axis, the number of patients at risk in each group is displayed at various time points.*

FDA Label Image

Figure 2 (Xeloda 03)

A Kaplan-Meier survival curve comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line) over 96 months since randomization. The y-axis shows survival probability from 0.0 to 1.0, while the x-axis represents months. A table below the graph lists the number of patients at risk for each group at different time points.*

FDA Label Image

Figure 3 (Xeloda 04)

A Kaplan-Meier survival curve chart showing estimated probability over time in days. It compares two treatment groups: 5-FU plus Leucovorin (Mayo Regimen) and Xeloda 1250 mg/sqm twice daily intermittent dosing. The chart includes a marked point around 391-392 days on the time axis.*

FDA Label Image

Figure 4 (Xeloda 05)

A Kaplan-Meier survival curve comparing the estimated probability over time (in days) between two groups: one treated with Docetaxel 100 mg/sqm every 3 weeks, shown with a dashed line, and another treated with Xeloda 1250 mg/sqm twice daily intermittently combined with Docetaxel 75 mg/sqm every 3 weeks, shown with a solid line. The graph shows survival probability declining over time, with marked time points at 128 and 186 days.*

FDA Label Image

Figure 5 (Xeloda 06)

A survival curve chart comparing estimated probability over time (days) between two groups: one treated with Docetaxel 100 mg/sqm every 3 weeks and the other with XELODA 1250 mg/sqm twice daily intermittent combined with Docetaxel 75 mg/sqm every 3 weeks. The graph shows survival probability declining over approximately 800 days, with marked median survival times indicated around 351 and 442 days for the groups, respectively.*

FDA Label Image

Principal Display Panel (150 mg Tablet Bottle Carton)

Label image of Xeloda capecitabine tablets, showing strength of 150 mg per tablet. The label includes prescription-only and hazardous drug warnings. The package contains 60 tablets and displays the CHEPLAPHARM name. The NDC is 61269-470-60.*

FDA Label Image

Principal Display Panel (500 mg Tablet Bottle Carton)

XELODA 500 mg tablets packaging label showing the active ingredient capecitabine. The label indicates each tablet contains 500 mg capecitabine, includes an Rx only symbol, a warning about the drug being hazardous, and states the package contains 120 tablets. The labeler CHEPLAPHARM is also shown.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.